Q3 Earnings Forecast for VNDA Issued By HC Wainwright

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Thursday, October 31st. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will post earnings per share of ($0.16) for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.48) EPS.

Several other research firms have also recently issued reports on VNDA. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Friday, November 1st. They issued a “hold” rating for the company. Cantor Fitzgerald upped their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Trading Down 1.2 %

Vanda Pharmaceuticals stock opened at $4.79 on Monday. The firm has a market cap of $279.21 million, a PE ratio of -25.21 and a beta of 0.77. Vanda Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $6.75. The stock’s 50 day simple moving average is $4.80 and its two-hundred day simple moving average is $5.24.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SageView Advisory Group LLC purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter worth approximately $34,000. Meeder Asset Management Inc. purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter worth $39,000. ORG Wealth Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at about $40,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 4,374 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Vanda Pharmaceuticals during the second quarter worth about $61,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.